Aditxt Inc. (NASDAQ: ADTX), a social innovation platform focused on accelerating health innovations, announced it will implement a 1-for-27 reverse stock split of its common stock, effective at the opening of trading on the Nasdaq Capital Market on May 18, 2026. The reverse split is intended to bring the company into compliance with Nasdaq’s minimum bid price requirement, reducing outstanding common shares from approximately 13.8 million to about 510,123, with the stock continuing to trade under the symbol ADTX.
The reverse stock split is a strategic move to address the company’s listing compliance. Nasdaq requires listed companies to maintain a minimum bid price of $1.00 per share. Aditxt’s stock has been trading below this threshold, prompting the need for action. By consolidating shares, the company aims to increase the per-share price to meet the Nasdaq requirement and avoid potential delisting. This move is critical for maintaining investor confidence and access to capital markets.
Aditxt operates a unique model that democratizes innovation, ensuring every stakeholder’s voice is heard and valued. The company currently runs four programs focused on autoimmunity, cancer and early disease detection, infectious diseases, and women’s health. The reverse split does not change the fundamental value of the company or the proportional ownership of shareholders, though it may affect liquidity and trading dynamics.
For more details, the full press release is available at https://ibn.fm/S1uMK. Investors seeking the latest news and updates relating to ADTX can visit the company’s newsroom at https://ibn.fm/ADTX.
The reverse split underscores the challenges faced by small-cap biotech companies in maintaining Nasdaq listing standards. For Aditxt, this is a necessary step to continue its mission of accelerating promising health innovations. The company’s ability to regain compliance will be closely watched by investors and industry observers as an indicator of its financial health and strategic direction.
